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Abstract
Background: We aimed to investigate the role of hypercoagulability on the risk of lifetime cardiovascular
recurrences after myocardial infarction or ischaemic stroke.
Methods: Young women (< 50 years) with either myocardial infarction (n = 197) or ischaemic stroke (n = 107) were
followed between 1995 and 2012 in the RATIO follow-up study. To determine whether hypercoagulability affects
the risk or recurrence, a coagulation score based on acquired and inherited markers was compiled and used in a
quartile analysis. Hazard ratios (HRs) obtained from Cox proportional models and adjusted for several cardiovascular
risk factors were used to compare quartiles of the coagulation score for the risk of recurrence.
Results: During a median follow-up of 19 years, 59 cardiovascular recurrences occurred. In patients with myocardial
infarction no association was found between a high prothrombotic score and recurrences (highest quartile vs
lowest quartile HR 0.7, 95% CI, 0.3–1.8). Conversely, ischaemic stroke patients with a high prothrombotic score
showed a doubling in risk of long-term cardiovascular recurrences (HR 1.9, 95% CI 0.6–6.3) compared with
ischaemic stroke patients and low levels of the score, with a dose response relationship.
Conclusions: An increased coagulation tendency might be associated with long-term cardiovascular risk in women
with ischaemic stroke, but not in women with myocardial infarction.
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Background
Young survivors of an arterial thrombotic event have an
increased mortality and morbidity compared with the
general population, mainly related to the high risk of
cardiovascular recurrences [1–3]. This is particularly im-
portant at a young age, because the impact on quality of
life and on socioeconomic costs, considering life expect-
ancy, is the highest [4, 5]. Therefore, there is an increas-
ing interest around secondary prevention strategies in
the young to target risk factors for recurrences after a
myocardial infarction or an ischaemic stroke event, the
two main forms of arterial thrombosis.
Previous studies have shown that classical risk factors
for the first episode, such as hypertension and hyperlipid-
aemia, are not associated with recurrences in both stroke
and myocardial infarction [3, 6]. It is well known that the
risk profile of a recurrent event can be different from that
of a first event and that often a risk factor is found to be
weaker for a second event than for a first [7, 8].
For the first cardiovascular event, we showed that an
increased clotting propensity is a risk factor for ischae-
mic stroke, whereas the risk of myocardial infarction is
only affected marginally [9–11]. No data are available
on the association between hypercoagulability and a
second arterial thrombotic event. The difference in the
role of coagulation in the aetiology of a first occurrence
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of myocardial infarction and ischaemic stroke might also
be relevant for the recurrence and prevention of these two
diseases, and raises the question whether secondary pre-
vention for ischaemic stroke and myocardial infarction
should differ more than it does now.
Therefore, we investigated the role of an increased co-
agulation propensity on the risk of recurrent arterial
thrombotic events in young women who survived myo-
cardial infarction or ischaemic stroke.
Methods
Patients
We used data from the Risk of Arterial Thrombosis in Re-
lation to Oral Contraceptives (RATIO) follow-up study,
based on subjects who participated in the RATIO case-
control study [12]. For the present study two groups of pa-
tients, subjects who survived either a myocardial infarction
or an ischaemic stroke, were included. Patient selection
within the RATIO case-control study has been described
in detail previously [13–15]. In summary, the RATIO study
included young women (between 18 and 49 years old) with
either a first myocardial infarction or ischaemic stroke
(index events) who consecutively presented to one of the
16 participating hospitals in the Netherlands between 1990
and 1995. Exclusion criteria were TIA (defined as an event
lasting < 24 h), haemorrhagic stroke, venous sinus throm-
bosis, carotid artery dissection, history of cardiovascular or
cerebrovascular diseases, severe illness, aphasia, or cogni-
tive impairment interfering with the questionnaire and not
speaking Dutch. Myocardial infarction was diagnosed by
the presence of clinical symptoms, elevated cardiac en-
zyme levels, and corresponding electrocardiographic
changes. Clinical symptoms of ischaemic stroke were
confirmed by either computed tomography or magnetic
resonance imaging. Ischaemic stroke of cardioembolic
origin was excluded by the presence of atrial fibrillation or
suggestive cardiac ultrasound imaging. All cases were in-
cluded from 1995 to 1998 [16]. The population-based
group of control women was identified by random digit
dialing and matched according to age, area of residence,
and year of event. Eligible as controls were women without
prior myocardial infarction and ischaemic stroke, who were
aged 18 to 49 years and who did not meet the exclusion
criteria that were used for selecting patients. All par-
ticipants were asked to fill in the same structured
questionnaire comprising questions on medical history
of cardiovascular risk factors. Smoking was defined as
having regularly smoked in the year before the index
date. Alcohol consumption was defined as drinking at
least one unit of alcohol per week. Body mass index
(BMI) was calculated as body weight (kg) divided by
height squared (m2). Women were classified as hyperten-
sive, diabetic or hypercholesterolaemic when they re-
ported a physician’s diagnosis or were taking medication
for these conditions before the index date. Family history
of cardiovascular disease was defined as the presence of
myocardial infarction, stroke or peripheral artery disease
below 60 years of age in first degree relatives.
Blood samples and buccal swabs were collected for
blood measurement of clotting factors and DNA ana-
lyses in a subset of women who initially participated in
the first phase of the RATIO study (205 participants
with myocardial infarction, 125 with ischaemic stroke
and 638 controls). To compensate for the loss of statistical
power in the ischaemic stroke group, we additionally re-
cruited 50 women between 1996 and 2001, leading to a
small difference in median time between event and blood
sampling between the two case groups (69months, range
38 to 117months, for myocardial infarction cases and 95
months, range 23 to 146months, for ischaemic stroke
cases). The interval between the initial event and blood
sampling minimises the risk of reverse causation as well
as the mixing of short and long-term effects of hypercoag-
ulability on cardiovascular risk. Blood draw procedures
and laboratory procedures are described in detail in the
previous publications [13–15]. All participants gave in-
formed consent and the study was approved by the ethics
committees of the participating hospitals [13].
In 2013, data on participants of the RATIO case-control
study were linked to the Dutch Register of death certifi-
cates and to the Dutch Hospital Data register by the
Central Bureau of Statistics of the Netherlands. The first
provides both primary and secondary causes of deaths
coded according to the International Statistical Classifi-
cation of Diseases and Related Health Problems 10th
Revision (ICD-10) classification. The second provides
electronic coverage of data on all hospital admissions in
the Netherlands since 1995. The data collected concern
the date of admission and discharge, diagnoses, and
surgical procedures from virtually all university and
general hospitals and most specialized clinics. Diagnosis
are encoded according to ICD 9th Revision (ICD-9).
Almost all personal (age, sex, date of birth and postal
code) and administrative data (date of admission, dis-
charge and death), and 84% of principal diagnoses were
found to be correctly encoded by a previous comparison
of a random sample of hospital admissions in the Dutch
Hospital Data register with information from hospital re-
cords [17]. For myocardial infarction, the percentage of
correctly encoded diagnosis has since been found to be
almost 100% [18].
Data from the RATIO case-control study were linked to
these registries through date of birth, sex, and postal code
of each RATIO participant. Individuals with information
leading to more than one person (e.g., twins or individuals
with the same date of birth in the same postal area) or to
nobody at all, were excluded from the analyses. The ori-
ginal RATIO case control study included 1376 women
Maino et al. BMC Cardiovascular Disorders           (2019) 19:55 Page 2 of 6
(248 myocardial infarction cases, 203 ischaemic stroke
cases and 925 controls). Of these women, 1168 (87%) were
successfully linked to the registries.
Outcomes
For this study prespecified outcomes were the first occur-
rence of an acute cardiovascular event, either myocardial
infarction or ischaemic stroke, whichever occurred first.
The outcome myocardial infarction includes the diag-
noses defined by the ICD-9-CM codes 4100 to 4109 and
the cause of death defined by the ICD-10 code I21. The
outcome ischaemic stroke includes the diagnosis defined
by the ICD-9-CM codes 433, 4330 to 4333, 4338, 4339,
434, 4340, 4341, and 4349 and codes 4350- to 4359
(transient ischaemic stroke), and the cause of death de-
fined by the ICD-10 codes I63 and I64. We chose to
include these two acute cardiovascular diseases, as these
will most likely lead to hospitalization and therefore
captured by the Dutch Hospital Data register.
Statistical analyses
Follow-up ended on the date of a first incident cardio-
vascular event of interest, the date of death, or 31st De-
cember 2012, whichever came first. Median follow-up
was calculated using the estimates of the censoring dis-
tribution for overall mortality.
To explore the influence of an increased coagulation
propensity on the risk of a recurrent cardiovascular
event we compiled an individual prothrombotic score
(coagulation score). The score was constructed with co-
agulation markers measured in both patient groups and
in control subjects, being: 1) tissue factor/tissue plas-
minogen activator induced clot-lysis time (CLT) as a
measure of fibrinolytic potential [19]; 2) antigen levels of
coagulation factors of the intrinsic coagulation system
(factor XII, FXII, and FXI and prekallikrein) [20]; 3)
inhibitor complexes of the serine proteases of the intrin-
sic coagulation system (C1 esterase inhibitor for FXIIa,
FXIa, Kallikrein, and antitrypsin inhibitor) as measures
of the activation of intrinsic coagulation factors [21]; 4)
a disintegrin-like and metalloprotease with thrombos-
pondin type 1 motif, member 13 (ADAMTS13) antigen
levels [22]; 5) von Willebrand factor (VWF) antigen
levels [22]; 6) antiphospholipid antibody tests (presence
of lupus anticoagulant detected with dilute Russell’s viper
venom time (dRVVT) reagents, IgG anticardiolipin anti-
body concentrations, IgG anti-β2-glycoprotein I concen-
trations and anti-prothrombin antibodies concentrations)
[9]; 7) presence of factor V Leiden (either heterozygous or
homozygous) [23, 24]; 8) presence of G20210A mutation
in the prothrombin gene (either heterozygous or homozy-
gous) [23, 24]; 9) presence of the homozygous form of the
methylenetetrahydrofolate reductase (MTHFR) C677T
[23, 24]. The score was based on the beta coefficients,
adjusted for matching variables, obtained from logistic re-
gression models for the association between each coagula-
tion marker and index ischaemic stroke. These analyses
were based on dichotomous exposures, with the 90th per-
centile of the control group distribution as cut off value, or
on the presence of the genetic variant, or on the test
positivity, whichever was the most appropriate. These
beta coefficients were summed so that the compiled
score represents the coagulation weighted prothrombo-
tic potential for each patient, with higher values of the
score corresponding to a higher levels of thrombotic
propensity.
To investigate whether high values of the coagulation
score increased the risk of a recurrent event, we applied
a Cox proportional hazard model based on the quartiles
of the prothrombotic score distribution as exposure
categories, with the lowest quartile as reference. The
model was adjusted for age, sex, body mass index, alco-
hol consumption, smoking history, diabetes mellitus,
hypertension, hyperlipidaemia and family history of a
cardiovascular event.
Results
The RATIO follow-up study included 226 patients with
myocardial infarction and 160 patients with ischemic
stroke followed for a median time of 18.7 years (IQR
17.5–20.5). Their baseline characteristics are depicted in
Table 1. The coagulation score could be calculated for
197 patients with myocardial infarction and 107 patients
with ischaemic stroke, for whom blood and biomarker
measurement were available (Fig. 1). Mean values of the
score were 1.08 (min − 0.36, max 5.73) in patients with







Age at the event, years (SD) 42.4 (6.1) 40.0 (7.5)
BMI, kg/m2 (SD) 27.1 (5.4) 25.5 (5.7)
Median follow-up, years (IQR) 18.6 (17.2–20.1) 18.9 (17.3–20.7)
Medical history, n (%)
Diabetes mellitus 11 (5%) 9 (6%)
Hypertension 56 (25%) 41 (26%)
Hyperlipidaemia 25 (11%) 9 (6%)
Alcohol consumption 138 (61%) 90 (57%)
Smoking 188 (83%) 100 (63%)
Cardiovascular family historya 145 (66%) 82 (56%)
BMI body mass index, SD standard deviation, IQR interquartile range
aData available for 97% of the subjects in the myocardial infarction group and
92% of the subjects in the ischaemic stroke group
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myocardial infarction and 2.06 (min − 0.28, max 9.03) in
patients with ischaemic stroke.
During follow-up, 36 (18%) patients with myocardial
infarction and 23 (21%) patients with ischaemic stroke
experienced a recurrent event, of which 11 and 4, re-
spectively, were fatal. Figure 2 shows the association be-
tween quartiles of the coagulation score and the risk of a
recurrent cardiovascular event, with the first quartile as
reference category. In patients with myocardial infarc-
tion high values of the coagulation score (i.e., high
thrombotic propensity) were not associated with an in-
crease in risk of a recurrent event compared with low
values of the score (i.e., low thrombotic propensity;
fourth quartile vs first quartile HR 0.7, 95% CI, 0.3–1.8).
On the contrary, a doubling of the risk of cardiovascular
recurrences was observed in patients with ischaemic
Fig. 1 Flow chart for study participants
Fig. 2 Hazard ratios for cardiovascular recurrence by quartiles of the coagulation score. Triangles indicate hazard ratios for cardiovascular
recurrences in patients with myocardial infarction by quartile of the coagulation score, whereas squares indicate hazard ratios for cardiovascular
recurrences in patients with ischaemic stroke by quartile of the coagulation score. Hazard ratios are obtained by Cox proportional hazard models
and are all adjusted for age, smoking, alcohol consumption, BMI, history of diabetes, hypertension, and hypercholesterolemia and family history of
a cardiovascular event. Solid lines indicate 95% confidence intervals. The y axis scale is logarithmic. q indicates quartile of the coagulation score.
The first quartile (q1) is the reference category
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stroke and high values of the coagulation score com-
pared with patients with low values, although with a very
wide confidence interval (fourth quartile vs first quartile
HR 1.9, 95% CI 0.6–6.3), with evidence of a “dose re-
sponse” relationship (second quartile vs first quartile HR
1.3, 95% CI, 0.3–5.1, and third quartile vs first quartile
HR 1.6, 95% CI, 0.5–5.6).
Discussion
Our findings suggest that an increased coagulation ten-
dency is associated, in a dose dependent manner, with a
decades long increased risk of cardiovascular recur-
rences in women with ischaemic stroke but not in
women with myocardial infarction. Although women with
ischaemic stroke and an overt cardiac-embolic-source
were excluded from this study, all other subtypes
were combined as data needed for classification were
not available [25]. This hampers the ability to better
elucidate the pathophysiological mechanisms beyond
our observation. However, we believe our finding may
have clinical relevance in the future, given its possible
implications for secondary prevention, especially in the
era of the direct oral anticoagulants (inhibitors of factor
IIa, and factor Xa) or even newer anticoagulants such as
FXI antisense oligonucleotides, that represent new treat-
ment options to establish a more targeted anticoagulation.
The direct clinical impact of our results is limited as we
did not set out to develop a formal risk prediction model
and therefore should also not be interpreted as such.
Future studies, with a more homogenous subsample
of stroke patients are needed to show the true added
value of markers of hypercoagulability in terms of
long-term risk prediction.
Patients enrolled in our study a few years after the
event, and therefore, patients suffering from early fatal
ischaemic stroke or myocardial infarction are not in-
cluded in the analyses. This implies that our results
should be applied to survivors of both ischaemic stroke
and myocardial infarction. In fact, including patients
from the moment of their stroke would mix long-term
and short-term effects, potentially hindering their
interpretation. The applied coagulation score included
several acquired and inherited markers of hypercoagu-
lability and was weighted on the risk of the index
ischaemic stroke event, since index ischaemic stroke
has been shown to be the arterial event in which hyper-
coagulability plays the largest role [10, 11]. In this way,
the coagulation score represents the individual pro-
thrombotic propensity. Even if our risk score does not
include all markers of coagulation, we were still able to
include 18 presumed markers of hypercoagulability as
they were measured in both case groups of the RATIO
study.
A possible limitation to our study is that recurrent ar-
terial cardiovascular events (both myocardial infarction
and ischaemic stroke) were not objectively confirmed,
but obtained from a national register (the Dutch Hos-
pital Data register). However, data collected in this
register have been found to be reliable (for myocardial
infarctions the percentage of corrected diagnosis was
almost 100%) [18]. In addition, even if any misclassifi-
cation was present in the register, it is likely to be
non-differential, and therefore, the comparison be-
tween myocardial infarction and ischaemic stroke is
unaffected. Another limitation is that, despite the long
follow-up, numbers of recurrent arterial cardiovascu-
lar events were small, leading to imprecision of the es-
timated rates (wide confidence intervals). Moreover,
we were unable to incorporate information on medi-
cation use during the follow-up period into our ana-
lyses. Some medications, such as anticoagulants,
antiplatelets and statins may have influenced the pro-
thrombotic score. However, the ischaemic stroke pa-
tients did not use anticoagulant as their stroke was of
non-cardioembolic origin. Antiplatelets and statins at
baseline have at most a marginal effect on measured co-
agulation factors, but given that prescription of these
drugs as such is not dependent on the prothrombotic
score, it is unlikely that this would have caused a
strong bias. Finally, we cannot exclude that our results
partly reflect a different involvement of inflammation in
the relationship between hypercoagulability and recur-
rences. Unfortunately, we do not have data in order
to investigate this hypothesis.
Conclusions
Our results show that an increased coagulation tendency
might be associated with long-term cardiovascular risk
in women with ischaemic stroke but not in women with
myocardial infarction.
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